Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy

Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy

The pathogenesis of glaucoma is strongly associated with the occurrence of autoimmune-mediated loss of retinal ganglion cells (RGCs) and additionally, recent evidence shows that specific antibody-derived signature peptides are significantly differentially expressed in sera of primary-open angle glau...

Full description

Bibliographic Details
Main Authors: Carsten Schmelter, Kristian Nzogang Fomo, Natarajan Perumal, Caroline Manicam, Katharina Bell, Norbert Pfeiffer, Franz H. Grus
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Journal of Clinical Medicine
Subjects:
glaucoma
autoimmunity
synthetic CDR peptides
neuroprotection
HTRA2
<i>Sus scrofa domestica</i>
Online Access:https://www.mdpi.com/2077-0383/8/8/1222

Similar Items

Similar Items